Finerenone CAS 1050477-31-0: A Crucial Component for Targeting Kidney and Cardiovascular Health
At NINGBO INNO PHARMCHEM CO.,LTD., we understand the pivotal role that specialized chemical compounds play in advancing healthcare. Finerenone powder, identified by its CAS number 1050477-31-0, is a prime example of such a compound, offering significant promise in the treatment of serious health conditions.
The therapeutic landscape for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) and associated cardiovascular complications is constantly evolving. Finerenone has emerged as a leading non-steroidal mineralocorticoid receptor (MR) antagonist, designed to offer a more targeted and potentially safer approach compared to older steroidal alternatives. Its mechanism of action focuses on blocking the adverse effects of aldosterone, a hormone that can exacerbate kidney damage and cardiovascular issues in these patient populations. This selectivity is a key feature that drives its development and application.
The synthesis of Finerenone is a complex process requiring expertise in organic synthesis. Manufacturers rely on high-purity intermediates like Finerenone powder to ensure the efficacy and safety of the final drug product. The precise chemical structure and the ability to produce it consistently are critical. As a vital pharmaceutical intermediate, its availability and quality directly impact the progress of research and the scalability of drug production. The ability to purchase Finerenone CAS 1050477-31-0 from reliable sources is essential for pharmaceutical companies.
The application of Finerenone extends to improving outcomes in diabetic nephropathy, a common and serious complication of diabetes that often leads to kidney failure. By intervening in the mineralocorticoid pathway, Finerenone offers a new therapeutic strategy to slow disease progression and reduce the risk of major adverse cardiovascular events. The ongoing research and clinical trials underscore the compound's potential to significantly impact patient care.
NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting the pharmaceutical industry with top-tier chemical products. Our Finerenone powder is manufactured under stringent quality controls to meet the demanding specifications of drug development and production. We aim to be a trusted partner for companies looking to leverage the therapeutic benefits of Finerenone in their innovative treatments.
Perspectives & Insights
Nano Explorer 01
“The therapeutic landscape for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) and associated cardiovascular complications is constantly evolving.”
Data Catalyst One
“Finerenone has emerged as a leading non-steroidal mineralocorticoid receptor (MR) antagonist, designed to offer a more targeted and potentially safer approach compared to older steroidal alternatives.”
Chem Thinker Labs
“Its mechanism of action focuses on blocking the adverse effects of aldosterone, a hormone that can exacerbate kidney damage and cardiovascular issues in these patient populations.”